Esperion Therapeutics | Frais De Vente Et D'Administration

Selling And Administration Expenses Changement Date
AbbVie USD 3.61B 273M 2023-12
Alnylam Pharmaceuticals USD 198.12M 1.05M 2023-12
Amarin USD 45.46M 5.5M 2023-09
Amgen USD 1.76B 424M 2023-12
Biogen USD 608.5M 179.7M 2023-12
BioMarin Pharmaceutical USD 275.02M 51.1M 2023-12
Cipla INR 10.91B 245.2M 2023-09
CSL USD 1.29B 219.4M 2023-06
Cytokinetics USD 44.11M 4M 2023-12
Daiichi Sankyo JPY 141.03B 4.45B 2023-09
Eli Lilly USD 1.92B 120.7M 2023-12
Geron USD 21.4M 3.05M 2023-12
Grifols EUR 300.32M 28.7M 2023-09
Halozyme Therapeutics USD 37.61M 2.34M 2023-12
Intra Cellular Therapies USD 104.72M 487K 2023-12
Ionis Pharmaceuticals USD 71.01M 1.06M 2023-12
Merck USD 2.75B 272M 2023-12
Moderna USD 470M 28M 2023-12
Pfizer USD 4.47B 1.27B 2023-12
PTC Therapeutics USD 76.29M 4.6M 2023-12
Regeneron Pharmaceuticals USD 737.7M 97.2M 2023-12
Sarepta Therapeutics USD 120.89M 2.33M 2023-09
United Therapeutics USD 128.6M 1000K 2023-12



Esperion Therapeutics Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2024.